13th Sep 2007 07:59
Citigroup Global Markets Limited13 September 2007 13th September, 2007 Not for distribution, directly or indirectly, in or into the United States orany jurisdiction in which such distribution would be unlawful. AstraZeneca PLC EUR 750,000,000 5.125% Notes due 15 January 2015 Launched pursuant to the Issuer's USD 5,000,000,000 EMTN Programme, dated 10 September 2007 Stabilisation Notice Citigroup Global Markets Limited (contact: Syndicate Desk; telephone: +44 (0) 207986 9000) hereby gives notice that the Stabilising Manager(s) named below maystabilise the offer of the following securities in accordance with CommissionRegulation (EC) No. 2273/2003 implementing the Market Abuse Directive (2003/6/EC). The securities: Issuer: AstraZeneca PLC Aggregate nominal amount: EUR 750,000,000 Description: 5.125% Notes due 15 January 2015 Offer price: 99.829% Other offer terms: Denominations EUR50k / Listing London Stabilisation: Stabilising Manager(s): Citigroup Global Markets Limited (Stabilisation Manager) Deutsche Bank (Stabilisation Manager) HSBC (Stabilisation Manager) Stabilisation period expected 12th August 2007to start on: Stabilisation period expected 30 days after the proposed issue date of the securitiesto end no later than: Maximum size of over-allotment 5% of the aggregate nominal amount stated above.facility: In connection with the offer of the above securities, the Stabilising Manager(s)may over-allot the securities or effect transactions with a view to supportingthe market price of the securities at a level higher than that which mightotherwise prevail. However, there is no assurance that the Stabilising Manager(s) will take any stabilisation action and any stabilisation action, if begun,may be ended at any time. This announcement is for information purposes only and does not constitute aninvitation or offer to underwrite, subscribe for or otherwise acquire or disposeof any securities of the Issuer in any jurisdiction. This announcement and the offer of the securities to which it relates are onlyaddressed to and directed at persons outside the United Kingdom and persons inthe United Kingdom who have professional experience in matters related toinvestments or who are high net worth persons within article 12(5) of theFinancial Services and Markets Act 2000 (Financial Promotion) Order 2005 andmust not be acted on or relied on by other persons in the United Kingdom. In addition, if and to the extent that this announcement is communicated in, orthe offer of the securities to which it relates is made in, any EEA Member Statethat has implemented Directive 2003/71/EC (together with any applicableimplementing measures in any Member State, the "Prospectus Directive") beforethe publication of a prospectus in relation to the securities which has beenapproved by the competent authority in that Member State in accordance with theProspectus Directive (or which has been approved by a competent authority inanother Member State and notified to the competent authority in that MemberState in accordance with the Prospectus Directive), this announcement and theoffer are only addressed to and directed at persons in that Member State who arequalified investors within the meaning of the Prospectus Directive (or who areother persons to whom the offer may lawfully be addressed) and must not be actedon or relied on by other persons in that Member State. This announcement is not an offer of securities for sale into the United States.The securities have not been, and will not be, registered under the UnitedStates Securities Act of 1933 and may not be offered or sold in the UnitedStates absent registration or an exemption from registration. There will be nopublic offer of securities in the United States. END This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Astrazeneca